Navigation Links
Johnson & Johnson Completes Tender Offer for Mentor Corporation
Date:1/23/2009

NEW BRUNSWICK, N.J., Jan. 23 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) today announced the expiration of the subsequent offering period of the cash tender offer through its wholly owned subsidiary, Maple Merger Sub, Inc., for all outstanding shares of common stock of Mentor Corporation (NYSE: MNT). The subsequent offering period expired, as scheduled, at 12:00 midnight (Eastern Time) on Jan. 22, 2009, and was not extended.

The depositary for the tender offer has advised Johnson & Johnson that, as of the expiration of the subsequent offering period, shareholders of Mentor had tendered approximately 31,806,675 shares of Mentor common stock (including approximately 565,142 shares subject to guaranteed delivery procedures), representing approximately 93.9% of Mentor's outstanding shares of common stock. According to the terms of the tender offer, all shares that were validly tendered have been accepted for payment.

Johnson & Johnson intends to complete the acquisition of Mentor through what is known as a "short-form merger," that is, without a vote or meeting of Mentor's remaining shareholders. In the merger, each of the remaining shares of Mentor common stock (other than shares owned by shareholders of Mentor who properly exercise their dissenters' rights under Minnesota law) will be converted into the right to receive $31.00 per share, less any required withholding taxes, in cash and without interest, which is the same amount per share that was paid in the tender offer. The merger is expected to occur as soon as practicable.

Following the merger, Mentor is expected to operate as a stand-alone business unit reporting through ETHICON, Inc., a Johnson & Johnson company, and Mentor's common st
'/>"/>

SOURCE Johnson & Johnson
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Johnson & Johnson to Participate in Bear Stearns 20th Annual Healthcare Conference
2. Draxis Health selected by Johnson and Johnson Consumer Companies, Inc. for major contract manufacturing relationship
3. Johnson & Johnson Campaign for Nursings Future Joins With AACN to Offer New Minority Nurse Faculty Scholars Program
4. Trust for Americas Health Receives $7.6 Million Grant from the Robert Wood Johnson Foundation to Advance the Quality and Impact of the Public Health System
5. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
6. Johnson & Johnson Tops Annual Pharmaceutical Company Rankings in a New Report From Industry-Leading Publication Scrip
7. Independence Technology, A Johnson & Johnson Company, Renews Its Contract With Creative Technology Services
8. Johnson & Johnson Launches Global Diabetes Institute to Provide State-of-The- Art Education, Training to Health Professionals
9. Robert Wood Johnson Foundation Announces $15.6 Million Grant to Apply Power of the Archimedes Model to Critical Health Care Decisions
10. UAN Mourns Passing of President Cheryl L. Johnson, RN
11. Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 According to the Nasal Polyps Treatment ... comprehensive guide that teaches people how to cure their ... uncovers to readers the horrible truth about conventional treatments for ... inside this book, people will learn how to prevent ... and nasal infections. , Nasal Polyps Treatment Miracle, as it ...
(Date:7/30/2014)... CA (PRWEB) July 30, 2014 ... and physician communication, launched an Observation Result (ORU) ... the hospital. pMD’s cardiology customers are using the ... revenue for their test interpretations for electrocardiograms, echocardiograms, ... tests in the hospital, the cardiology system produces ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Paul Mata, CEO ... Make More Money in 30 Days” E-book. The e-book includes ... use to make extra cash. Examples include downloading and utilizing ... free websites that help people monetize the assets they didn't ... unused items they can find in their garage. , ...
(Date:7/29/2014)... July 30, 2014 Dignity Sciences Limited, ... completion of a Phase I trial with DS107G, an ... This study was a randomized, placebo-controlled, double-blind, single-ascending and ... safety, pharmacokinetics and effect of food on DS107G in ... safety profile of DGLA following both single and multiple ...
(Date:7/29/2014)... Use of electroacupuncture (EA) a form of ... between pairs of acupuncture needles produces significant ... little as eight weeks for early stage breast ... use of aromatase inhibitors (AIs) to treat breast ... examining the intervention led by researchers at the ...
Breaking Medicine News(10 mins):Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 2Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 3Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 2Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 3Health News:Create Indestructible Wealth Launches Innovative E-Book: “Realistic Ways to Make More Money in 30 Days” 2Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 3
... S.C., Dec. 11 African-American women in South Carolina are 37 ... have a death rate that is about 61 percent higher, according ... Arnold School of Public Health. , (View a video of Dr. ... in the nation in deaths from cervical cancer. , The study ...
... 10, 2009 The advice of a pediatrician to place infants ... important motivator in getting parents to follow these recommendations and a ... plummeted since the "Back to Sleep" campaign was launched in 1994, ... shown that placing infants on their backs to sleep limits the ...
... those in uncommitted relationships , FRIDAY, Dec. 11 ... are no more likely than those in committed relationships ... In the study, University of Minnesota researchers analyzed the ... 20.5, who were asked about their sexual behaviors and ...
... , Immediate action needed to protect public ... 11 It,s been almost two weeks since the Food ... of a new safety assessment of the toxic plastics chemical ... and pregnant women are left unprotected from this hormone-disrupting compound ...
... , AUSTIN, Texas, Dec. 11 ... pleased to offer free upgrades to their customers currently using Dragon ... is faster and more stable, providing up to 99% accuracy ... with Windows7, 64bit and 32bit operating systems. New features include voice ...
... , BEIJING, Dec. ... CCM ) ("CMS" or "the Company"), operator of the largest,network ... of,revenues and the total number of centers in operation in ... Depositary Shares,("ADSs"), each representing three ordinary shares of the Company, ...
Cached Medicine News:Health News:'Disease of Poverty': University of South Carolina Releases Journal on Cervical Cancer, Health Disparities 2Health News:'Disease of Poverty': University of South Carolina Releases Journal on Cervical Cancer, Health Disparities 3Health News:Physician advice a key motivator in baby's sleep position 2Health News:Physician advice a key motivator in baby's sleep position 3Health News:Casual Sex Doesn't Cause Emotional Damage: Study 2Health News:When Will FDA Speak Out on Toxic Plastics Chemical BPA? 2Health News:Recorders.com Offers Free Dragon Medical 10.1 Upgrades 2Health News:Concord Medical Services Holdings Limited Announces Pricing of Initial Public Offering on the New York Stock Exchange 2Health News:Concord Medical Services Holdings Limited Announces Pricing of Initial Public Offering on the New York Stock Exchange 3
(Date:7/29/2014)... CAMBRIDGE, Mass. and HERZLIYA PITUACH, ... Inc. (OTCQX and NASDAQ OMX First North Premier, ... announces today that it has initiated the screening of ... trial exploring the safety and efficacy of bertilimumab in ... open-label trial will enroll 10-15 patients who will receive ...
(Date:7/29/2014)... 29, 2014  Sequenom, Inc. (NASDAQ: SQNM ... solutions, today reported total revenues of $39.8 million for ... compared to revenues of $24.5 million for the second ... segment, which was sold on May 30, 2014, has ... its results have been excluded from continuing operations for ...
(Date:7/29/2014)... 2014  EnteroMedics Inc. (NASDAQ: ETRM ), ... treat obesity, metabolic diseases and other gastrointestinal disorders, today ... Thursday, August 7, 2014 at 11:00 AM Eastern Time ... June 30, 2014 and to provide a business update. ... quarter conference call may be accessed by dialing (877) ...
Breaking Medicine Technology:Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 2Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 3Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 4Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 5Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 2Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 3Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 4Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 5Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 6Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 7Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 8Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 9Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 10Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 11Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 12Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 13Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 14Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 15Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 16EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3
... Corporation (NASDAQ: VOLC ), a leading developer and ... the diagnosis and treatment of coronary and peripheral vascular disease, ... the third quarter of fiscal 2011 on Monday, October 31. ... discuss its financial results and operating activities open to all ...
... 17, 2011 Archimedes Pharma Ltd., and its subsidiary, ... nasal spray is now available by prescription in U.S. ... pain in cancer patients 18 years of age and ... to opioid therapy for their underlying persistent cancer pain. ...
Cached Medicine Technology:Volcano Corporation Schedules Third Quarter Conference Call, Webcast 2Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 2Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 3Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 4Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 5Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 6Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S. 7
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: